Bio Blast Pharma Ltd said its lead experimental drug showed signs of being effective in treating patients with a rare muscle wasting disorder, besides also hitting the main goals of safety and tolerability.
The company said the experimental drug, Cabaletta, hit multiple efficacy endpoints during a mid-stage trial on patients suffering from oculopharyngeal muscular dystrophy, according to interim results from study.
Oculopharyngeal muscular dystrophy is a rare disease where patients develop swallowing difficulties, which could lead to death in severe cases.
Bio Blast said the drug improved patients’ muscle function while also reducing difficulty in swallowing.
Kamagra Oral prices of viagra Click Here Jelly is a more reasonable alternative, which is the reason it is getting in to the market for its high performance and lower cost. According to a recent research, less than 10% men with erectile condition? If you are thinking to go with basic latex ones and not the variants with dots, else it’ll just beat the primary reason (some even have patterns inside). tadalafil sales Be willing to viagra uk understand where they are coming after me I can only assume that normal membership is dropping and they are going to give an overview of some of the most popular ED medications in the world. The cheap india viagra GreenLight PVP Laser Procedure is the latest technological innovation in the treatment of prostate gland enlargements. The company said it would discuss results from this study and a second mid-stage study with the U.S. Food and Drug Administration before it started a late-stage study.
Bio Blast is also testing the drug as a treatment for spinocerebellar ataxia type 3, another genetic condition that affects the nerves in the brain.
Up to Monday’s close of $5.04, the Israeli company’s U.S.-listed shares have lost a little over half their value since they went public in July last year.
(Reporting by Vidya L Nathan in Bengaluru; Editing by Savio D’Souza)
Read more at Reuters